This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

JAY SHANON, M.D.

AMA Arch Derm. 1958;77(1):119-120.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The purpose of this study was to evaluate the effect of a new tranquilizing agent, perphenazine (Trilafon) in dermatologic patients. No effort was made to determine the critical influence of perphenazine on the dermatitis, but only the effect on pruritus and the subjective state of the individual. It was also the purpose to determine whether or not the pharmacologic agent has any undesirable side-effects. This study of a new tranquilizer was done with the active cooperation of the Department of Psychiatry, and cases were used from both dermatology and psychiatry.

Material and Methods

Perphenazine (1-[2-hydroxyethyl]-4-[3-(2-chloro-10-phenthiazyl)-propyl]-piperazine) is a phenothiazine derivative with behavioral effects in animals and men generally similar to chlorpromazine. It is, however, five to seven times as potent as the latter in its effects on behavior without increase in toxicity.

Three hundred eight patients, 205 women and 103 men, with several skin diseases were . . . [Full Text PDF of this Article]

Author Affiliations
Cincinnati

Footnotes
Submitted for publication June 24, 1957.

Fellow in Psychosomatic Dermatology of the Department of Dermatology and the Psychosomatic Service of the Department of Psychiatry of the College of Medicine of the University of Cincinnati. Perphenazine furnished by Dr. Harry V. Pifer, Division of Clinical Research, Schering Corporation.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?